See more : DEMIRE Deutsche Mittelstand Real Estate AG (DMRE.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Ventyx Biosciences, Inc. (VTYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ventyx Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Beijing Strong Biotechnologies, Inc. (300406.SZ) Income Statement Analysis – Financial Results
- Sonder Holdings Inc. (SOND) Income Statement Analysis – Financial Results
- Motorola Solutions, Inc. (0K3H.L) Income Statement Analysis – Financial Results
- Kyokuto Kaihatsu Kogyo Co.,Ltd. (7226.T) Income Statement Analysis – Financial Results
- BNK Banking Corporation Limited (BBC.AX) Income Statement Analysis – Financial Results
Ventyx Biosciences, Inc. (VTYX)
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 941.00K | 470.00K | 30.00K | 0.00 | 0.00 |
| Gross Profit | -941.00K | -470.00K | -30.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 175.77M | 87.74M | 58.48M | 6.37M | 3.55M |
| General & Administrative | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Other Expenses | 0.00 | 41.00K | -5.45M | -1.00K | -1.00K |
| Operating Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Cost & Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Interest Income | 15.07M | 4.67M | 78.00K | 358.00 | 146.00 |
| Interest Expense | 0.00 | 0.00 | 99.00K | 358.00K | 146.00K |
| Depreciation & Amortization | 158.00K | 470.00K | 30.00K | 7.05M | 4.18M |
| EBITDA | -207.84M | -107.96M | -67.12M | 0.00 | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.99M | -113.14M | -67.15M | -7.05M | -4.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.03M | 4.71M | -16.60M | -21.12M | -147.00K |
| Income Before Tax | -192.96M | -108.43M | -83.75M | -28.17M | -4.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -470.00K | -5.38M | 358.00K | 146.00K |
| Net Income | -192.96M | -107.96M | -78.37M | -28.53M | -4.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| EPS Diluted | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| Weighted Avg Shares Out | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
| Weighted Avg Shares Out (Dil) | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Lawsuit - VTYX
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX
Levi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
Investors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
Source: https://incomestatements.info
Category: Stock Reports